Cell Therapy Industry Group Welcomes its 4,000th member
By Dr. Matthew Watson
I'm pleased to point out that today the LinkedIn Cell Therapy Industry Group welcomed its 4,000th member today.
The Cell Therapy Industry group was created to serve as a network of those in the cell therapy industry. The group acts as a vehicle for referrals, networking, information, and facilitating collaboration. The group's focus is on the activities of companies in and serving the space.
The group began in July 2008. It took 2.5 years to reach the first 1000 members, 9 mos to reach 2,0000, 6 months to reach 3,000, and 6 months to meet today's 4,000 member mark.
As is typical, there is a very high percentage of passive participants but the group benefits from an avid group of participants who post, share, exchange, and debate on a range of topics ranging from regulatory, clinical, commercial, scientific, manufacturing, financial, and other topics of interest to the group.
As the group has grown I've noted two trends pertaining to the composition of the membership: (a) having tapped out the c-level suite, growth is increasingly coming from down the hierarchy of the corporate food chain and including those in the operational trenches, and (b) a much higher ratio of new members of late is from outside the US, presumably as LinkedIn increasingly penetrates OUS markets.
We strive hard to maintain the quality of the participation by screening each applicant, deleting off-topic posts, moving promotional posts to the "promotions" tab" and encouraging a balance of news-sharing with useful discussion threads.
I'm proud to say the group has become a vibrant and valuable part of the sector due to the hard work and contributions of all involved.
As these kind of virtual networks become exponentially larger and provide different value than the professional societies representing the sector, I will be fascinated to watch if and how this affects how sectors like our interact and how this will impact the traditional value proposition of member-based professional societies.
If you are not a member of the LinkedIn Cell Therapy Industry Group, check it out.
--Lee
- Commercialization of Regenerative Medicine: Learning from Spin-Outs - April 28th, 2013
- 2013 Annual Regenerative Medicine Industry Report - April 21st, 2013
- Cell Therapy Blog welcomes 2013 - January 6th, 2013
- The Accuracy of Adipose Stem Cell Doses - December 23rd, 2012
- A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments - December 16th, 2012
- The ROI on pant-wearing and other social media tips - December 16th, 2012
- Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. - December 2nd, 2012
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. - November 4th, 2012
- CIRM addresses some tough questions. Is it all just glass towers and basic research? - October 21st, 2012
- Cell therapy portfolio outperforms major indices year-to-date - October 14th, 2012
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. - September 30th, 2012
- Anticipated short-term cell therapy industry clinical milestones - September 30th, 2012
- Two lessons I learned this week. - September 16th, 2012
- Are some cell counts too good to be true? Why some companies' product data may mislead. - September 2nd, 2012
- Is the cell therapy sector outperforming the major indices? - August 12th, 2012
- FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) - July 29th, 2012
- Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing - June 17th, 2012
- Industry-sponsored cardiovascular cell therapies. Some metrics. - May 27th, 2012
- Cell-based Cancer Immunotherapies. Some metrics.. - May 20th, 2012
- Another > $100M month for companies in the cell therapy space - May 6th, 2012
- Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? - March 11th, 2012
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? - January 1st, 2012
- Inactive and recently failed or terminated phase III or II/III cell therapy trials - December 18th, 2011
- Recently approved cell therapy products - December 18th, 2011
- Active phase III or II/III cell therapy trials - December 11th, 2011
- Sabrina Cohen Foundation Thanks Stem Cell Researchers - November 27th, 2011
- Commercializing Cell-based Regenerative Medicines - November 13th, 2011
- Cell Therapy & Regenerative Medicine Domains Available - September 25th, 2011
- Commercial-stage Cell Therapy Companies and Products - September 18th, 2011
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy - September 18th, 2011
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. - August 14th, 2011
- Clinical trial costs - July 31st, 2011
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations - July 10th, 2011
- In vivo cell trafficking just took a leap forward - July 3rd, 2011
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals - February 12th, 2011
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong - January 15th, 2011
- Careers in cell therapy & regenerative medicine - October 11th, 2010
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations - August 12th, 2010
- The changing face of PR and why it matters to regenmed - June 12th, 2010
- Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 - May 22nd, 2010
- Google to Invest in Regenerative Medicine - May 5th, 2010
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. - April 30th, 2010
- Stem cells for a Webby! - April 28th, 2010
Regenerative Medicine
Comments Off on Cell Therapy Industry Group Welcomes its 4,000th member |
November 11th, 2012
This author published 5912 posts in this site.Share
